Loading…
Acrivon Therapeutics, Inc. is projected to rise to $2.13 by 2027, a +9% move from its current price of $1.96. ACRV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.89 | $1.96 | $2.03 | -0.02% |
| Jul 14 | $1.87 | $1.96 | $2.06 | -0.05% |
| Jul 15 | $1.85 | $1.96 | $2.08 | -0.07% |
| Jul 16 | $1.83 | $1.96 | $2.10 | -0.09% |
| Jul 17 | $1.81 | $1.96 | $2.11 | -0.11% |
| Jul 18 | $1.80 | $1.96 | $2.13 | -0.14% |
| Jul 19 | $1.79 | $1.96 | $2.14 | -0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.79 | $1.96 | $2.14 | -0.16% |
| Week 2 | $1.72 | $1.95 | $2.22 | -0.32% |
| Week 3 | $1.67 | $1.95 | $2.28 | -0.47% |
| Week 4 | $1.62 | $1.95 | $2.34 | -0.63% |
| Week 5 | $1.59 | $1.94 | $2.38 | -0.79% |
| Week 6 | $1.55 | $1.94 | $2.43 | -0.94% |
| Week 7 | $1.52 | $1.94 | $2.47 | -1.10% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops oncology medicines. It uses its generative phosphoproteomics platform to identify patients whose tumors are predicted to be sensitive to each specific medicine.
The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program.
The company was incorporated in 2018 and is based in Watertown, Massachusetts.
ACRV trades in the Healthcare sector under the symbol ACRV. The current price is $2.04, with a market cap of $87.32M and a rank of 4277.
The 30-day technical range runs from $1.62 to $2.57, with a sentiment of NEUTRAL, RSI14 at 70, and moving averages of $1.72 (SMA50) and $1.87 (SMA200). The stock shows support at $1.38 and resistance at $2.04.
Forecast data show a path from 2026 through 2050 with varying levels of upside. The 2026 min $1.29, avg $2.04, max $2.64; ROI 0; sentiment NEUTRAL. From 2030 onward, the outlook becomes more bullish, with 2030 avg $2.80 and max $4.31 (ROI 37.1%); continuing to 2040 with avg $6.37, max $11.74 (ROI 212%); and 2050 with avg $13.93, max $28.55 (ROI 582.9%), all with a BULLISH sentiment.
A major floor 42.5% below — a decisive break under it would weaken the trend.
The nearest floor, 29.6% below — buyers have tended to step in here.
The nearest ceiling, 4.6% above — a clean break opens room to run.
A major ceiling 25.9% above — clearing it would confirm fresh momentum.
Key ACRV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACRV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.94 | Buy | $1.94 | Buy |
| MA 10 | $1.84 | Buy | $1.85 | Buy |
| MA 20 | $1.69 | Buy | $1.76 | Buy |
| MA 50 | $1.73 | Buy | $1.71 | Buy |
| MA 100 | $1.67 | Buy | $1.74 | Buy |
| MA 200 | $1.87 | Buy | $1.94 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.35 | Neutral |
| Stoch RSI (14) | 66.39 | Neutral |
| CCI (20) | 120.95 | Buy |
| Williams %R (14) | -19.15 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 20.25 | Buy |
| Bollinger %B (20,2) | 0.88 | Neutral |
| Stochastic %K (14) | 80.85 | Sell |
| TRIX (15) | 0.34 | Buy |
| Awesome (5,34) | 0.30 | Buy |
| Ultimate (7,14,28) | 69.63 | Neutral |
| Momentum (10) | 0.38 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 2.06 | Sell |
| ADX (14) | 22.53 | Buy |
| ATR (14) | 0.06 | Info |
The short-term technical picture is NEUTRAL.
RSI14 is 70, and the 50-day simple moving average is $1.72 while the 200-day simple moving average is $1.87.
There is a defined support at $1.38 and a resistance at $2.04. The 30-day range runs from $1.62 to $2.57.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.29 | $1.96 | $2.54 | 0% | Neutral | |
| $1.65 | $2.13 | $2.92 | +9% | Neutral | |
| $1.76 | $2.35 | $3.37 | +20% | Neutral | |
| $1.66 | $2.29 | $3.40 | +17% | Neutral | |
| $2.03 | $2.87 | $4.39 | +46% | Bullish | |
| $2.65 | $3.83 | $6.02 | +96% | Bullish | |
| $2.60 | $3.86 | $6.19 | +97% | Bullish | |
| $2.71 | $4.11 | $6.74 | +110% | Bullish | |
| $2.75 | $4.25 | $7.10 | +117% | Bullish | |
| $2.61 | $4.12 | $7.00 | +110% | Bullish | |
| $3.98 | $6.88 | $12.57 | +251% | Bullish | |
| $7.50 | $15.30 | $31.01 | +680% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.29 | $1.96 | $2.36 | +0.00% |
| August 2026 | $1.60 | $1.90 | $2.33 | -2.95% |
| September 2026 | $1.60 | $1.92 | $2.39 | +0.94% |
| October 2026 | $1.65 | $2.00 | $2.51 | +4.01% |
| November 2026 | $1.64 | $1.99 | $2.53 | -0.31% |
| December 2026 | $1.62 | $1.98 | $2.54 | -0.39% |
Click any year to see its month-by-month ACRV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ACRV price prediction for 2026 points to an average of $1.96 (low $1.29, high $2.54) — a potential gain of 0% on today's $1.96. A consolidation phase looks the most probable path here.
In 2027, ACRV is projected to trade between $1.65 and $2.92, averaging $2.13 — a potential gain of +9% from today's $1.96. That is up +9% on the projected 2026 average. Price action looks broadly range-bound.
Acrivon Therapeutics, Inc.'s 2028 outlook centres on $2.35, within a $1.76 to $3.37 range. That is up +10% on the projected 2027 average. That marks a +20% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, ACRV could reach as high as $3.40, with a base case around $2.29 and support toward $1.66 — roughly +17% from $1.96. Price action looks broadly range-bound.
Expect ACRV to range from $2.03 to $4.39 through 2030. The $2.87 average target implies a +46% move from current prices. That is up +25% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ACRV price prediction for 2031 points to an average of $3.83 (low $2.65, high $6.02) — a potential gain of +96% on today's $1.96. Momentum favours further upside here.
In 2032, ACRV is projected to trade between $2.60 and $6.19, averaging $3.86 — a potential gain of +97% from today's $1.96. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Acrivon Therapeutics, Inc.'s 2033 outlook centres on $4.11, within a $2.71 to $6.74 range. That is up +7% on the projected 2032 average. That marks a +110% change versus current levels. Momentum favours further upside here.
By 2034, ACRV could reach as high as $7.10, with a base case around $4.25 and support toward $2.75 — roughly +117% from $1.96. Buyers look set to stay in control over this stretch.
Expect ACRV to range from $2.61 to $7.00 through 2035. The $4.12 average target implies a +110% move from current prices. That is -3% versus the projected 2034 average. Momentum favours further upside here.
The ACRV price prediction for 2040 points to an average of $6.88 (low $3.98, high $12.57) — a potential gain of +251% on today's $1.96. Buyers look set to stay in control over this stretch.
In 2050, ACRV is projected to trade between $7.50 and $31.01, averaging $15.30 — a potential gain of +680% from today's $1.96. That is up +122% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ACRV today (≈ 510.204082 ACRV) could be worth
$7,803.93
+$6,803.93 (+680%) by 2050 · US Dollar
Based on the average projected ACRV price of $15.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACRVwould be worth at today's price.
$1,000 invested in ACRV on Jul 10, 2025 (≈ 740.740728 ACRV) would be worth
$1,451.85
+$451.85 (+45.2%) today · 1.45× · US Dollar
Based on a ACRV entry price of $1.35 vs. today's $1.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.72 | $1,139.53 | +14.0% |
| 1 month ago | $1.38 | $1,420.29 | +42.0% |
| 3 months ago | $1.56 | $1,256.41 | +25.6% |
| 6 months ago | $1.63 | $1,202.45 | +20.2% |
| 1 year ago | $1.35 | $1,451.85 | +45.2% |
| All time (3.7y) ago | $16.64 | $117.79 | -88.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACRV forecast.
Our base-case forecast reaches $3.90 around 2033.
Implied market cap at $3.90: $166.93M
The multi-year forecast shows a bullish trajectory from 2030 onward. In 2030 the avg price is $2.80 with a max of $4.31 and an ROI of 37.1%, with a BULLISH sentiment. The year 2040 projects an avg of $6.37 and a max of $11.74, with an ROI of 212% and a continued BULLISH stance.
By 2050 the forecast calls for an avg of $13.93 and a max of $28.55, with an ROI of 582.9% and remains BULLISH.
The forecast also provides earlier year context: 2026 min $1.29, avg $2.04, max $2.64, ROI 0, sentiment NEUTRAL. These are projections and should be treated as estimates rather than guarantees.
Tap a question to reveal the answer.
In 2030 the forecast shows min $1.97, avg $2.80, max $4.31 with ROI 37.1% and a BULLISH sentiment.
The forecast shows a bullish trajectory from 2030 onward with rising averages and positive ROI (e.g., 2031 ROI 82.5%, 2032 ROI 83.3%, 2040 ROI 212%, 2050 ROI 582.9%). These are estimates, not guarantees.
Yes. The forecast lists max prices above $5 starting in 2031 (2031 max $5.89; 2032 max $6.05; 2033 max $6.54; 2034 max $6.82; 2035 max $6.68), and higher later (2040 max $11.74; 2050 max $28.55).
Current price is $2.04 and market cap is $87.32M.
The 30-day range is $1.62 to $2.57. RSI14 is 70, SMA50 is $1.72, SMA200 is $1.87. There is support at $1.38, resistance at $2.04, and sentiment is NEUTRAL.
Acrivon Therapeutics, Inc. Community Discussion
0Share your Acrivon Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.